Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms

Executive Summary

The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.

Advertisement

Related Content

At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
Pharma's Love Affair With Dealmaking: No End In Sight
Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
China Reforms Welcome, But More Needed – Frazier
Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
Congressional Dems Generating Heat, But No Hearings, On Rx Prices

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel